YAP levels also limit the clinical efficacy of RAF and MEK inhibitors.
It is well established that active YAP promotes cell proliferation 6 , epithelial-to-mesenchymal transition, invasion and metastasis 7, 8 . But what triggers YAP activation? In KRASsilenced pancreatic cancer cells, chromosomal amplifications increase YAP1 copy number 9 . However, no amplifications are found in colorectal and lung cancers, implying regulation of the YAP protein at the transcriptional level. In uveal melanoma, transcription is stimulated by translocation of YAP into the nucleus 10 . The transcriptional activity of YAP is mediated by different transcription factors, depending on the tumor type: in pancreatic cancer, YAP interacts with TEAD2 to regulate the cell cycle and DNA replication 9 , whereas in colon and lung cancers its interaction with FOS, a member of the AP-1 transcription factor family, induces epithelial-to-mesenchymal transition 11 . The findings of Lin et al. expand the role of YAP to mediating drug resistance, in the context of both oncogenic BRAF and NRAS. Although this and other recent studies highlight the complexity of YAP regulation, they also emphasize its value as a potential therapeutic target.
YAP in the bull's-eye
As active YAP promotes resistance to RAFand MEK-targeted inhibitor therapy, disrupting YAP activity is predicted to enhance the response to RAF and MEK inhibitors in patients with an activated MAPK pathway. This includes patients who harbor either BRAF or RAS gene mutations. As activating mutations in RAS genes are among the most frequent events in numerous human carcinomas 12 and no inhibitors targeting active RAS proteins are available, further investigating this new avenue of concurrently targeting MEK and YAP is essential (Fig. 1) . Indeed, specific They identified YAP1 (encoding Yes-associated protein, YAP) as a key factor in resistance to RAF inhibitor therapy. YAP is one of the two main effectors of the Hippo tumor-suppressor pathway. Silencing of YAP1 increased cell sensitivity to RAF and MEK inhibitors, with this effect demonstrated across different genetic backgrounds and in a variety of tumor models-lung, melanoma, colon, thyroid and pancreatic cancer cell lines. Combined YAP and RAF or MEK inhibition was found to be lethal in both BRAF-and RAS-mutant tumors. Notably, these results suggest that the synthetic lethal relationship between YAP and MEK inhibitors is more significant in cells harboring mutations in BRAF than in RAS genes.
It takes two to tango
The authors suggest that YAP is a survival input that acts in parallel to the well-characterized MAPK signaling cascade, preventing apoptosis and enhancing overall survival signaling. According to this model, when both MAPK signaling and YAP are active, cells proliferate and resist apoptosis, leading to active disease progression. 'Turning off ' only MAPK signaling results in decreased proliferation, but cells remain resistant to apoptosis and the response to treatment is thus incomplete. Only when both the MAPK pathway and YAP are inactivated do inhibition of proliferation and activation of apoptosis follow, leading to a complete response to treatment.
Assessment of YAP expression in tumors that harbored mutant BRAF showed increased YAP levels in patients with a worse response to RAF inhibitors. Furthermore, elevated YAP levels were found in tumors that acquired resistance in comparison to tumor samples obtained before treatment from the same patients. Thus, not only is YAP a biomarker of decreased response to RAF and MEK inhibitors in BRAF-mutant patients, but increased Cancer is a disease of the genome, in which mutations disrupt genes that control normal cellular proliferation and lead to malignant growth. In spite of the overwhelming complexity of cancer, recent years have brought significant advances in understanding its genetic landscape and the molecular mechanisms underlying tumor initiation and progression 1 . Several key 'driver' genes, central to cancer development, were identified and characterized 2 . Analysis of the molecular roles of these genes and the pathways in which they reside enabled the development of promising targeted therapies. One example is RAF and MEK inhibitors, which target oncogenic BRAF and its downstream effectors, preventing the abnormal activation of the mitogen-activated protein kinase (MAPK) pathway common to many malignancies 3 . Despite significant clinical responses to such targeted therapies, full remission is rarely durable, as nearly all tumors acquire resistance 4 . Resistance mechanisms, which are poorly understood and vary considerably, are extremely important to decipher, as an understanding of them allows the design of novel targeted therapies aimed at preventing resistance. In this issue of Nature Genetics, Trever Bivona and colleagues add another piece to the puzzle of cancer genetics by identifying YAP as a key survival input that mediates resistance by acting in parallel to other known pathways in tumor progression 5 .
YAP behind the wheel
The authors performed a genetic screen to identify factors increasing the efficacy of the RAF inhibitor vemurafenib in cancer cells harboring the BRAF V600E alteration. 13 and show some promise in animal models 14 . Importantly, this work, as well as other studies 15 , emphasizes the need to develop drugs targeting master transcriptional regulators, common to a wide range of malignancies.
Finally, this report emphasizes the fact that in many cases different mutations activate similar pathways and may be treated by similar drugs, regardless of the tissue in which the tumor originated. However, the full complexities of cancer-associated genetic alterations and the intricate interactions between different players, as well as various drug resistance mechanisms, still elude us. Although the road to efficient treatment is still long, these findings are likely to encourage further research into targeting YAP in tumors and are likely to have clinical impact. 
Replication fidelity and cancer
In eukaryotic cells, multiple mechanisms limit the DNA replication error rate to roughly 1 × 10 −10 errors per base replicated (about 1 error per cell division in humans). DNA polymerases ε and δ replicate the bulk of the genome; in addition to performing highly accurate initial incorporation, they both contain proofreading capabilities through their 3′→5′ exonuclease activity. Errors that escape proofreading are subsequently repaired by the MMR complex. Inherited heterozygous deleterious variants in any one of the MMR genes replication, and germline MMR deficiency renders these individuals at high risk for diverse malignancies beginning at a young age. In this issue, Adam Shlien, Peter Campbell, Uri Tabori and colleagues report exome and genome sequencing of tumors from individuals with bMMRD 2 . Unexpectedly, they found that malignant brain tumors each contained a somatic mutation in one of the proofreading DNA polymerases, POLE or POLD1, leading to extraordinarily mutationprone tumors, fittingly described as ultrahypermutated. Individuals with the rare cancer predisposition syndrome biallelic mismatch-repair deficiency (bMMRD; MIM 276300) are born with loss-offunction variants of both copies of a mismatchrepair (MMR) gene (MLH1, MSH2, MSH6 or PMS2) 1 . The MMR complex is a major cellular mechanism for assuring the fidelity of DNA avalanching mutations in biallelic mismatch repair deficiency syndrome
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Tumors from pediatric patients generally contain relatively few somatic mutations. a new study reports a striking exception in individuals in whom biallelic germline deficiency for mismatch repair is compounded by somatic loss of function in dna proofreading polymerases, resulting in 'ultra-hypermutated' malignant brain tumors.
